RAPID BIOCHEMICAL DETERMINATION OF CONGENITAL DISORDERS OF GLYCOSYLATION

The new technology enables the primary detection of congenital disorders of glycosylation (CDG). It uses specially prepared biochips or microplates for the analysis of total serum glyco-epitopes. **A highly sensitive, simple and rapid method** for the primary detection of CDG in human serum or blood plasma samples by evaluating the signal ratio of their reaction with a specific combination of lectins.

AREA OF APPLICATION

Diagnosis of diseases in which the glycan formula of proteins in the blood changes, especially congenital disorders of glycosylation. The speed, sensitivity and simplicity of this technology allow its use also for routine CDG screening.

STAGE OF DEVELOPMENT AND PROTECTION

- **functionality verified** in laboratory conditions, TRL 4
- **priority patent application**

COMPETITIVE ADVANTAGE

- simplicity and speed of achieving the result
- significant reduction in sample quantity requirements
- use of commercially available reagents with guaranteed quality
- use of commonly available reading devices - microplate readers
- possibility of application in automated analyzers
- low price

WE ARE LOOKING FOR AN INDUSTRIAL PARTNER FOR LICENSING/SELLING THE TECHNOLOGY

CHEMICKÝ ÚSTAV SAV
INSTITUTE OF CHEMISTRY SAS

For more information please contact:

Ing. Anton Bittner, PhD., MBA
+421 903 203 930
bittner@up.upsav.sk

TTO SAS
Technology Transfer Office
Slovak Academy of Sciences